Operating Expenses - Prostatype Genomics AB (STO:PROGEN) - Alpha Spread
P

Prostatype Genomics AB
STO:PROGEN

Watchlist Manager
Prostatype Genomics AB
STO:PROGEN
Watchlist
Price: 0.019 SEK -7.32% Market Closed
Market Cap: 18.8m SEK
Have any thoughts about
Prostatype Genomics AB?
Write Note

Prostatype Genomics AB
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prostatype Genomics AB
Operating Expenses Peer Comparison

Comparables:
BIOG B
BONEX
VITR
SOBI
BIOA B

Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
P
Prostatype Genomics AB
STO:PROGEN
Operating Expenses
-kr43m
CAGR 3-Years
-29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Operating Expenses
-kr508.9m
CAGR 3-Years
-17%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Operating Expenses
-kr609.8m
CAGR 3-Years
-31%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Operating Expenses
-kr5.6B
CAGR 3-Years
-137%
CAGR 5-Years
-68%
CAGR 10-Years
-38%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Operating Expenses
-kr13.9B
CAGR 3-Years
-24%
CAGR 5-Years
-23%
CAGR 10-Years
-23%
BioArctic AB
STO:BIOA B
Operating Expenses
-kr300.5m
CAGR 3-Years
-34%
CAGR 5-Years
-9%
CAGR 10-Years
N/A

See Also

What is Prostatype Genomics AB's Operating Expenses?
Operating Expenses
-43m SEK

Based on the financial report for Dec 31, 2023, Prostatype Genomics AB's Operating Expenses amounts to -43m SEK.

What is Prostatype Genomics AB's Operating Expenses growth rate?
Operating Expenses CAGR 3Y
-29%

Over the last year, the Operating Expenses growth was -46%. The average annual Operating Expenses growth rates for Prostatype Genomics AB have been -29% over the past three years .

Back to Top